Dataset Information


Preferences for Adult Pneumococcal Vaccine Recommendations Among United States Health Care Providers.

ABSTRACT: INTRODUCTION:In 2014, the Advisory Committee on Immunization Practices (ACIP) of the US Centers for Disease Control and Prevention (CDC) recommended 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all adults aged???65 years, with a commitment to revisit the recommendation for PCV13 because of declining vaccine-type disease. The Evidence-to-Recommendation framework used by the ACIP includes review of evidence regarding feasibility and stakeholder acceptability, but no surveys of vaccinator preferences have been published in the literature. METHODS:Physicians (N?=?700), physician assistants (N?=?100), pharmacists (N?=?100), and nurse practitioners (N?=?100) who recently prescribed, administered, or recommended adult pneumococcal vaccine were surveyed in March 2018. Object-case best-worst scaling was used to assess preferences among potential recommendation scenarios: retaining the then-current 2014 recommendation without a scheduled re-evaluation, retaining with a scheduled re-evaluation, revising PCV13 to Category B (retaining PPSV23 as Category A), removing PCV13 (retaining PPSV23 as Category A), and removing both PCV13 and PPSV23. RESULTS:Providers' most preferred recommendations were retaining the 2014 recommendation with another planned re-evaluation (52.6%) and retaining the then-current recommendation without planned re-evaluation (40.0%). Few preferred changing PCV13 to Category B (3.2%), removing PCV13 (3.7%), or removing both pneumococcal vaccines (0.5%). CONCLUSIONS:The majority of vaccinators surveyed preferred to retain the 2014 recommendation, either with another scheduled reassessment or indefinitely. FUNDING:Pfizer, Inc.


PROVIDER: S-EPMC6856229 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2014-01-01 | S-EPMC4003344 | BioStudies
1000-01-01 | S-EPMC4945555 | BioStudies
2018-01-01 | S-EPMC5774021 | BioStudies
2014-01-01 | S-EPMC4896606 | BioStudies
2019-01-01 | S-EPMC6605716 | BioStudies
2015-01-01 | S-EPMC4635730 | BioStudies
2019-01-01 | S-EPMC6605822 | BioStudies
2015-01-01 | S-EPMC4521829 | BioStudies
2018-01-01 | S-EPMC6149703 | BioStudies
1000-01-01 | S-EPMC6016414 | BioStudies